ALLERGY THERAPEUTICS PLC

Regulatory Filings • Oct 24, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3117N

Allergy Therapeutics PLC

24 October 2016

24 October 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Annual Report and Accounts

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that the Annual Report and Accounts for the year ended 30 June 2016 are available on the Company's website in the Investor Relations section. They can be located at: www.allergytherapeutics.com/media/1241/allergytherapeutics_ra_15-16.pdf

Printed copies of the Annual Report and Accounts for the year end 30 June 2016 were posted to shareholders on 22 October 2016, together with the Notice of the Annual General Meeting.

ENDS

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

allergytherapeutics@consilium-comms.com

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSBDBDGSXDBGLS